Exciting development for #N4P today - Launch of Nuvec Oncology Treatment Programme.
This potentially opens up a third colossal market, after vaccine delivery x2 (injection and oral).
The really exciting thing about this Co is that its asset, Nuvec, is already developed and..1/4
This potentially opens up a third colossal market, after vaccine delivery x2 (injection and oral).
The really exciting thing about this Co is that its asset, Nuvec, is already developed and..1/4
https://twitter.com/MylesMcNulty/status/1324265180281344000
...largely refined. It now need only prove consistent in-vivo success for its three target applications (oncology injection; vaccine injection; vaccine oral), and it can start out-licensing Nuvec.
And that's the core of the investment proposition: Nuvec is a platform tech. 2/4
And that's the core of the investment proposition: Nuvec is a platform tech. 2/4
It can be licensed out to multiple parties for multiple targets/applications. #N4P will receive upfront and milestone payments as the licensee takes the drug / vaccine (using Nuvec as the delivery platform) through the clinic.
N4P's cost base is exceptionally low; yet... 3/4
N4P's cost base is exceptionally low; yet... 3/4
...it could start building out its revenue base quite considerably in 2021.
Nuvec need only be successful in 1 of the 3 target applications for #N4P to likely enjoy major upside from its current mkt cap of £10m.
R/R is incredibly attractive right now, in my view. 4/4
Nuvec need only be successful in 1 of the 3 target applications for #N4P to likely enjoy major upside from its current mkt cap of £10m.
R/R is incredibly attractive right now, in my view. 4/4
• • •
Missing some Tweet in this thread? You can try to
force a refresh
